Focus: Butterfly Network develops a subscription-based portable ultrasound device platform with AI-assisted imaging capabilities targeting multiple therapeutic areas. The company is a publicly traded medical device innovator focused on democratizing ultrasound technology.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Growing — net +6 jobs in 30d
13 jobs added vs 7 removed. Steady team buildout.
Best fit for engineers, product managers, and commercial professionals seeking device-market exposure; poor fit for traditional drug-development or clinical-operations careers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Butterfly Network
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Butterfly Network's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Butterfly Network Stock And Other AI Healthcare Names With Real Clinical Use - simplywall.st
Butterfly Network Stock And Other AI Healthcare Names With Real Clinical Use simplywall.st
BFLY|Butterfly Network Inc|Price:8.025|Chg%:+0.915 - TradingKey
BFLY|Butterfly Network Inc|Price:8.025|Chg%:+0.915 TradingKey
Terray Therapeutics co-founder Eli Berlin explains approach to AI drug discovery - qz.com
Terray Therapeutics co-founder Eli Berlin explains approach to AI drug discovery qz.com
What This Butterfly Network Filing Means Against $121 Million in Guidance and a Stock Up 260% - The Motley Fool
What This Butterfly Network Filing Means Against $121 Million in Guidance and a Stock Up 260% The Motley Fool
Butterfly Network Director Jonathan M. Rothberg disposes of USD 29.23 million in common shares - Bitget
Butterfly Network Director Jonathan M. Rothberg disposes of USD 29.23 million in common shares Bitget
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 MarketBeat
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Considerations for Pre-deployment Planning in Point-of-Care Ultrasound Program Implementation: A HIMSS-SIIM Enterprise Imaging Community Whitepaper in Collaboration with AIUM.
Quantitative Liver Fat Assessment by Handheld Point-of-Care Ultrasound: A Technical Implementation and Pilot Study in Adults.
Showing 5 of 6 publications